ADMA Biologics sees 24% ASCENIV revenue growth in Q2 despite lowered long-term targets
ADMA Biologics experienced challenges earlier this year but showed recovery in Q2 with ASCENIV revenue up 24% and a strong 69% gross margin. The company lowered its long-term targets but improved receivable collections have boosted investor confidenc...
